The clinical application of 1.1 class ad new drug piperidmethyl ketone in South China new drug and health hospital was accepted

Recently, Guangzhou biomedical and Health Research Institute and Health Research Institute of Chinese Academy of Sciences and Guangdong South China new drug development center class 1.1 chemical new drug piperidmethyl ketone (referred to as "AD16") applied for new drug clinical research in November 2014, which has been accepted by the State Food and drug administration Compound AD16, as a representative of the major innovative chemical drugs of South China new drug and Health Institute, has a new target, a new structure and global independent intellectual property rights Compared with other R & D projects, the incidence of Alzheimer's disease is complex, the effect of R & D intervention of Alzheimer's disease drugs at home and abroad is limited, and the failure rate is high, so it is difficult to achieve breakthroughs in international new drug development South China new drug and Health Institute, as a representative of Guangdong's new drug creation ability, started strong cooperation in 2009 After five years of collective research, self-designed and synthesized, AD16 compounds were obtained through pharmacological screening The drug has novel structure and superior properties It has applied for 2 national invention patents and 1 PCT patent application AD16 can become a new generation of heavy drugs for the treatment of Alzheimer's disease This compound has a revolutionary breakthrough in Alzheimer's disease as a neuroinflammatory inhibitor, and points out a new direction for future anti Alzheimer's drugs The preclinical pharmacodynamic study showed that the mechanism of action of AD16 was different from that of traditional drugs, and the effect of AD16 was equivalent to that of donepezil and memantine, which were currently on the market, and the drug-forming effect of AD16 was better than that of the same kind of foreign developed varieties Through other preclinical studies, including pharmacy, acute toxicity experiment, pharmacokinetics and a series of experimental studies, the project has been evaluated from different aspects It is proved that AD16 has clear target, definite effect, large safety window, good safety, excellent drug-forming performance and good development prospect The successful application of AD16 indicates that the research and development of the drug has made important progress In addition, because the inflammatory mechanism of this kind of ring by ring causes other neurodegenerative diseases in addition to Alzheimer's disease, AD16 also has obvious protective effect on neuron damage caused by acute stroke, Parkinson's disease and brain trauma, with a broad market prospect Brief introduction of Research Institute: Guangdong South China new drug development center It is a science and technology private non enterprise unit initiated by many government departments such as Guangdong Provincial Science and technology department and jointly funded by many key pharmaceutical enterprises and scientific research institutes As one of the key innovation platforms in the outline of Pearl River Delta reform and development plan (2008-2020), the center has been incorporated into the national new drug creation system, and has undertaken and completed the national "11th Five Year Plan" section The construction of "South China comprehensive new drug research and development technology platform", a major technical project It is an important carrier for Guangdong Province to gather and integrate innovative resources and accelerate the industrialization of new drug creation projects, and a core accelerator for the pharmaceutical industry of Guangdong Province and even the whole South China region Guangzhou Institute of biomedicine and health of CAS is jointly established by CAS, Guangdong Provincial People's government and Guangzhou Municipal People's government The president responsibility system under the leadership of the Council is implemented in the Institute The establishment committee of the central organization approved the establishment of 200 researchers.